Moreover, in patients at high fracture risk its beneficial effects were shown in older men under androgen-deprivation therapy for prostate cancer, and women who receive adjuvant aromatase inhibitor for breast cancer. This evidence concerns the gene CYP19A1 and Familial prostate cancer.